James J. Hartman

Cardiac Myosin Activation Enhances Contractility While Preserving Myocardial Energetics Compared With β-Adrenergic Stimulation

This study compares CK-138 and dobutamine, showing CK-138 improves cardiac contractility without worsening myocardial energetics, unlike dobutamine which depletes ATP and shifts metabolism toward glycolysis.

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEF

This paper describes ulacamten, a novel cardiac myosin inhibitor with distinct binding and inhibitory properties compared to existing CMIs, showing efficacy in improving cardiac function in a rodent model of HFpEF.